Cancer immunotherapy (CIT), primarily represented by PD-1/PD-L1 inhibitors, has become a fashionable treatment approach and made substantial breakthroughs in the treatment of multi-solid tumors (94–96). The gene discussed is CD274; the disease is cancer.